License agreement signed for Vectavir, Vectatone and Silence

License agreement signed for Vectavir, Vectatone and Silence

Following a very strong sales increase for all products, Omega Pharma and Avia Pharma has decided to expand their co-operation.

From January 1st 2018 Avia Pharma will handle all commercial aspects of Vectavir, Vectatone and Silence in the Nordics.

“Avia Pharma is proud of the trust Omega Pharma has put in us. We will continue to develop and strengthen all products under this license agreement” says Jacob Calmvik, CEO of Avia Pharma